Is Breast Cancer Gene-Expression Profiling Cost-Effective in Community Practice? | Cancer Network | The Oncology Journal

Is Breast Cancer Gene-Expression Profiling Cost-Effective in Community Practice? | Cancer Network | The Oncology Journal

Jan 15, 2018 Vol 32 No 1

DIGITAL EDITION

Is Breast Cancer Gene-Expression Profiling Cost-Effective in Community Practice?

• Bryant Furlow

Wednesday, January 17, 2018

• Breast Cancer, Practice & Policy

Using gene expression profile (GEP) tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested, according to an economic simulation analysis published in the Journal of Clinical Oncology.